16 July 2022
By Lizzie Roberts – Daily Telegraph Health Correspondent
Quote
Around 4,000 patients could be given the twice-a-day pills, which can boost chances of staying disease-free by a third
Early-stage breast cancer patients will be offered a twice-a-day pill on the NHS which can boost their chance of staying disease-free by a third.
Around 4,000 women can now benefit from the drug after it was approved by the National Institute for Health and Care Excellence (Nice).
Abemaciclib, made by Eli Lilly, is suitable for those with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery.
Results from a clinical trial showed that people having the drug with hormone therapy had a more than 30 per cent higher chance of their cancer not coming back following surgery compared with hormone therapy alone.
Baroness Morgan of Drefelin, chief executive at Breast Cancer Now, said: "It's fantastic thousands of women with this type of primary breast cancer will now have an additional treatment option available on the NHS to help further reduce the risk of the disease coming back.
"The fear of breast cancer returning or spreading to other parts of their body and becoming incurable can cause considerable anxiety for so many women and their loved ones.
"New effective treatments such as abemaciclib, which can offer more women the chance to further reduce the risk of the disease recurring, are therefore extremely welcome and this is an important step-change in the drug options available for this group of patients."
Thousands more eligible
Around 50,000 people a year are diagnosed with breast cancer in England.
HER2-negative breast cancer is the most common type, accounting for around 70 per cent of all breast cancers. It is estimated that early breast cancer comes back after initial treatment in around a third of people.
Last year, NICE approved abemaciclib for patients with HER2-negative breast cancer which has spread to other parts of the body.
But today’s announcement means thousands more people will be eligible for the treatment.
The drug targets and attacks proteins in cancer cells which allow the cancer to divide and grow.
The treatment is normally expensive for 56 150mg-tablets, but Eli Lilly has agreed a confidential NHS discount.
End of quote
Source - UK Daily Telegraph.
Comment
I very much hope the MHMS might be able to obtain a supply of the breakthrough drugs with an arrangement with the British Government to help breast cancer patients in the Solomon Islands – please try.
Yours sincerely
Frank Short
